Basic information Overview Pharmacokinetics Indication Mode of action Adverse reactions Precautions Reference Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Nervous system drugs >  Antidepressants, Antimanics drugs >  Amitriptyline hydrochloride

Amitriptyline hydrochloride

Basic information Overview Pharmacokinetics Indication Mode of action Adverse reactions Precautions Reference Safety Supplier Related

Amitriptyline hydrochloride Basic information

Product Name:
Amitriptyline hydrochloride
Synonyms:
  • Amiplin
  • Normaln
  • Amitriptyline Hydrochloride (200 mg)
  • Methanol (test Amitriptyline HCl, 1.0 mg/mL as free base)
  • 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride
  • Amitriptyline hydrochloride 98+%
  • Amitriptyline hydrochloride solution
  • 3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride
CAS:
549-18-8
MF:
C20H24ClN
MW:
313.86
EINECS:
208-964-6
Product Categories:
  • ELAVIL
  • Adrenoceptor
  • Biogenic Amine Transport Inhibitors
  • Biogenic Amine Transport InhibitorsObesity Research
  • Neurotransmission
  • Amines
  • Neurotransmission (Obesity)
  • Neurotransmitters
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
Mol File:
549-18-8.mol
More
Less

Amitriptyline hydrochloride Chemical Properties

Melting point:
196-197°C
Flash point:
11 °C
storage temp. 
2-8°C
solubility 
H2O: soluble
form 
powder
pka
9.4(at 25℃)
color 
white to off-white
PH
4.5~6.0 (10g/l, 25℃)
Water Solubility 
almost transparency
Merck 
14,487
CAS DataBase Reference
549-18-8(CAS DataBase Reference)
EPA Substance Registry System
Amitriptyline hydrochloride (549-18-8)
More
Less

Safety Information

Hazard Codes 
T,F,N,Xn
Risk Statements 
23/24/25-36/37/38-42/43-63-39/23/24/25-11-50/53-36-22
Safety Statements 
22-26-36/37/39-45-36/37-16-61-60-7
RIDADR 
UN 2811 6.1/PG 3
WGK Germany 
3
RTECS 
HO9450000
TSCA 
Yes
HazardClass 
6.1(b)
PackingGroup 
III
HS Code 
29214990
Toxicity
LD50 in mice, rats (mg/kg): 350, 380 orally; 65, 75 i.p. (Tobe)

MSDS

More
Less

Amitriptyline hydrochloride Usage And Synthesis

Overview

Amitriptyline hydrochloride is a kind of dibenzocycloheptene-derivative tricyclic antidepressant(TCA) and analgesic. The TCAs has similar structure with phenothiazines, containing a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amitriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, amitriptyline exerts a positive effect on mood. TCAs take effect through acting as potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs such as amitriptyline has a more potent inhibitory effect on serotonin reuptake than secondary amine TCAs, such as nortriptyline[1]. TCAs can also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs might be related to the overall increase in serotonergic neurotransmission. In addition, TCAs can also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Amitriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use)[1].
Amitriptyline was one of the first successful antidepressants developed and has been widely used for the treatment of depression since the early 1960s. As early as in 1964, Lance and Curran reported that amitriptyline was effective in tension-type headache independent of the antidepressant effect and a positive effect in migraine was reported in 1973 [2,3]. Thus, amitriptyline is an old, well-known drug not only for the treatment of depression but also for primary headaches. The chemical structure of the tricyclic antidepressant, amitriptyline, is shown in FIGURE 1.

Figure 1 the chemical structure of the amitriptyline

Pharmacokinetics

Amitriptyline is lipid-soluble and rapidly absorbed after oral administration with peak concentrations achieved after 3–4 h. The bioavilability is relatively low(45%) because of a large first-pass effect. The drug is distributed widely throughout the body and is highly bound to both plasma and tissue proteins[5].
Amitriptyline is mainly metabolized in the liver and the major metabolite, nortriptyline, is pharmacologically active and has also been used for primary headache prophylaxis[4]. Nortriptyline blocks the re-uptake of NE and to a lesser extent 5-HT. Formation of nortriptyline and other metabolites is mediated by cytochrome phosphatase CYP2D6. The half-life of amitriptyline ranges from 13 to 36 h. The metabolites are mainly excreted in the urine. Steady-state plasma concentrations of amitriptyline and nortriptyline are achieved within 7–10 days. Metabolism is slower in elderly patients, which may result in increased plasma concentrations. The pharmacokinetics of amitriptyline is characterized by large interpatient variability and there is no clear relationship between plasma concentrations and analgesic effect[5].
Amitriptyline can interact dangerously with monoamine oxidase (MAO) inhibitors, resulting in hypertensive crisis or serotonin syndrome. Amitriptyline has potentially dangerous interactions with biogenic amines, such as NE, which normally are removed from their site of action by neuronal uptake. L-dopa administered together with amitriptyline increases the risk of hypertension and cardiotoxic effects. Some selective serotonin re-uptake inhibitors, such as fluoxetine and paroxetine and some neuroloptics, compete with amitriptyline for liver metabolism, which may result in toxic plasma concentrations of amitriptyline. Barbiturates and many anticonvulsant agents (particularly carbamazepine) lower plasma concentrations of amitriptyline by increasing hepatic metabolism. The anticholinergic activity of amitriptyline can add to that of antiparkinsonism agents, antipsychotic drugs, or to other compounds with antimuscarinic activity. Amitriptyline can block the centrally mediated antihypertensive action of clonidine[6].

Indication

Amitriptyline is indicated for the treatment of the following conditions: major depressive disorder in adults; the management of neuropathic pain in adults, the prophylactic treatment of chronic tension type headache (CTTH) in adults and the prophylactic treatment of migraine in adults[1].
In addition, it is also used for the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products. This medicinal product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis. -Other off-label uses include irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia[1].

Mode of action

Amitriptyline inhibits the presynaptic re-uptake of serotonin(5-HT) and norepinephrine(NE) in the CNS, thus potentiating the activity of these neurotransmitters. Beyond this, amitriptyline is a potent blocker of muscarinic cholinergic receptors, H1 histamine receptors, α1-adrenergic receptors and several 5-HT receptors, such as, 5-HT2A receptors, while the affinity for α2-adrenergic receptors is low[7,8]. With prolonged treatment amitriptyline may decrease β-adrenergic receptor density and may downregulate or upregulate several receptor systems, such as γ-aminobutyric acid(GABA), adenosine and 5-HT receptors. Moreover, amitriptyline potentiates the effect of endogenous opioids and may act as a N-methyl-D-aspartate(NMDA) receptor antagonist[9,10].
The prophylactic effect of amitriptyline seem unrelated to its antidepressant effect, both in migraine and tension-type headache and it can not be ascribed solely to the inhibition of 5-HT re-uptake because the selective serotonin re-uptake inhibitors are ineffective in headache prophylaxis[21,22,11-13]. It is possible that interaction with 5-HT receptors or blockade of ion channels, such as activated sodium channels, could be of importance in migraine[14–16]. Moreover, an effect on central pain pathways via inhibition of 5-HT and NE re-uptake, potentiation of endogenous opioids, or attenuation of central sensitization via NMDA receptor antagonism could play a role[17]. In tension-type headache, the latter-mentioned effects on central pathways are probably of major importance, but the peripheral analgesic actions of amitriptyline could also play a role[12,13,17–19]. A recent study found that amitriptyline elicits its analgesic effect in chronic tension-type headache by reducing the transmission of painful stimuli from myofascial tissues rather than by reducing overall pain sensitivity. It was suggested that this effect could be caused by a segmental reduction of central sensitization in combination with a peripheral antinociceptive action[20].

Adverse reactions

Commons side effects include tremors, dizziness, headache, dry mouth, constipation, and nausea[23]. For nervous system, side effects may include Ataxia, disturbance in attention, dizziness, dysarthria/speech disorders, dysgeusia, drowsiness, headache, paresthesia, somnolence, tremors, convulsions, akathisia and polyneuropathy. Cardiovascular diseases may include atrioventricular(AV) block, bundle branch block, electrocardiogram(ECG) abnormal, electrocardiogram QRS complex prolonged, electrocardiogram QT prolonged, orthostatic hypotension, palpitations, tachycardia, collapse conditions, hypertension, worsening of cardiac failure. Gastrointestinal side effects[23] may include constipation, diarrhea, dry mouth, nausea, tongue edema and vomiting. Respiratory side effects may include allergic inflammation of the pulmonary alveoli, allergic inflammation of the lung tissue, alveolitis, congested nose and Loffler's syndrome. Psychiatric side effects may include aggression, agitation, confusional states and libido decrease. Metabolic side effects[23] may include hyponatremia, thirst, weight increase.

Precautions

Amitriptyline should be administered with caution in patients with urinary retention, prostatic hypertrophy, increased ocular pressure, narrow angle glaucoma, constipation, impaired liver function, or cardiovascular disease and with care in elderly patients because of the anticholinergic effects. It should be avoided in patients with heart block, arrhythmias, immediately after myocardial infarction, in those with urinary retention, or severe liver disease and during pregnancy and breastfeeding[7]. Overdosage with amitriptyline can produce coma, seizures, hypertension, electrocardiographic abnormalities and arrhythmias. Death from amitriptyline overdosage is primarily due to cardiac arrest. This is of great concern when treating patients with depression but less often a problem when treating primary headaches. Serious adverse events may be seen after intake of 10–15 mg amitriptyline per kg of bodyweight[7].

Reference

  1. https://www.drugbank.ca/drugs/DB00321
  2. Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1, 1236–1239 (1964).
  3. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J. Neurol. Neurosurg. Psychiatry 36, 684–690 (1973).
  4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55, 754–762 (2000).
  5. Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 8, 459–476 (1996).
  6. Weber S. Drug interactions with antidepressants. CNS Special Edition 1, 47–55 (1999).
  7. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17, 2S–18S (1997).
  8. Westenberg HG. Pharmacology of antidepressants: selectivity or multiplicity. J. Clin. Psychiatry 60(Suppl. 17), 4–8 (1999).
  9. Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann.Neurol. 13, 160–164 (1983).
  10. Watanabe Y, Saito H, Abe K. Tricyclic antidepressants block NMDA receptormediated synaptic responses and induction of long-term potentiation in rat hippocampal slices. Neuropharmacology 32, 479–486 (1993).
  11. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch. Neurol. 36, 695–699 (1979).
  12. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch. Neurol. 44, 486–489 (1987).
  13. Bendtsen L, Jensen R, Olesen J. A nonselective (amitriptyline) but not a selective (citalopram), serotonin re-uptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J. Neurol. Neurosurg. Psychiatry 61, 285–290 (1996).
  14. Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalalgia 17, 85–92 (1997).
  15. Terron JA. Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur. J. Pharmacol. 439, 1–11 (2002).
  16. Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 8, 459–476 (1996).
  17. Bendtsen L. Sensitization: its role in primary headache. Curr. Opin. Investig. Drugs 3, 449–453 (2002).
  18. Cerbo R, Barbanti P, Fabbrini G, Pascali MP, Catarci T. Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenetic implications. Headache 38, 453–457 (1998).
  19. Sawynok J, Reid AR, Esser MJ. Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain 80, 45–55 (1999).
  20. Bendtsen L, Jensen R. Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 20, 603–610 (2000).
  21. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 17, 73–80 (1997).
  22. Mathew NT, Bendtsen L. Prophylactic pharmacotherapy of tension-type headache. In: The Headaches. 2 ed. Olesen J, Tfelt-Hansen P, Welch KM (Eds). Lippincott, Williams and Wilkins, MD, USA, 667–673 (2000).
  23. https://www.drugs.com/sfx/amitriptyline-side-effects.html

Description

Amitriptyline (hydrochloride) (CRM) (Item No. 19031) is a certified reference material categorized as a tricyclic antidepressant. This product is intended for analytical forensic applications. This product is also available as a general research tool .

Chemical Properties

White to Off-White Solid

Originator

Elavil HCl Merck Sharp and,Dohme,US,1961

Uses

vasoconstrictor

Uses

Amitriptyline hydrochloride is a tricyclic antidepressant drug. Amitriptyline hydrochloride inhibits the norepinephrine and serotonin transporters but has a high affinity for α1-adrenergic, serotonin and muscarinic acetylcholine receptors.

Uses

Amitriptyline hydrochloride has been used:

  • as an antidepressant to study its effects on social behavior and memory in transgenic for acid sphingomyelinase (t-ASM) mice
  • as a tricyclic antidepressant to analyze its effects on glucocorticoid receptor function in whole human blood
  • as an anti-depressant to study its effects on scratching and locomotion behavior in chloroquine-induced mouse

Manufacturing Process

Phthalic anhydride is reacted with phenylacetic acid to form 3- benzylidenephthalide which is then hydrogenated to 2-phenethylbenzoic acid. Conversion to the acid chloride followed by intramolecular dehydrochlorination yields the ketone, 5H-dibenzo[a,d]cyclohepten-5-one. The ketone undergoes a Grignard reaction with 3-(dimethylamino)propyl chloride to give 5-(γ- dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene.
Then, as described in US Patent 3,205,264, a solution of 5-(γ- dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene (42 grams; 0.153 mol) in 105 ml of ethanol is hydrogenated over Raney nickel (1.5 grams) at 65°C under an initial hydrogen pressure of 450 lb. After 1 mol of hydrogen is absorbed (3.5 hours), the reaction mixture is filtered to remove the catalyst and is acidified with 80 ml of 2.5 N hydrochloric acid (0.2 mol). The acidic solution is concentrated to dryness under vacuum and is flushed three times with 100 ml of benzene to remove residual water. The solid residue then is dried under vacuum at 40°C to yield 44.9 grams (94% of theory) of the product, MP 187-189.5°C, equivalent weight 307, ultraviolet absorption A% 2380432. Recrystallization from isopropyl alcohol and ether affords the product in high purity.
In practice it is usually used as hydrochloride.

brand name

Elavil (AstraZeneca); Endep (Roche).

Therapeutic Function

Antidepressant

General Description

Amitriptyline, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride,5-(3-dimethylaminopropylidene)-10,11-dihydro-5Hdibenzo[a,d]cycloheptene hydrochloride (Elavil), is one ofthe most anticholinergic and sedative of the TCAs. Becauseit lacks the ring-electron–enriching nitrogen atom ofimipramine, metabolic inactivation mainly proceeds not at theanalogous 2-position but at the benzylic 10-position (i.e.,toluene-like metabolism predominates). Because of the 5-exocyclic double bond, E- and Z-hydroxy isomers are producedby oxidation metabolism. Conjugation produces excretablemetabolites. As is typical of the dimethyl compounds,N-demethylation occurs, and nortriptyline is produced, whichhas a less anticholinergic, less sedative, and more stimulantaction than amitriptyline. Nortriptyline is a SNERI; thecomposite action of drug and metabolite is nonselective.

Biochem/physiol Actions

Tricyclic antidepressant; inhibits the norepinephrine and serotonin transporters with Kis of 100 nM and 14.7 nM, respectively; high in vitro affinity for α1-adrenoceptors, serotonin and muscarinic acetylcholine receptors.

Clinical Use

Tricyclic antidepressant:
Depression, used especially where sedation is required
Neuropathic pain (unlicensed)
Migraine prophylaxis (unlicensed)

Safety Profile

Poison by ingestion, intraperitoneal, intravenous, and subcutaneous routes. Human systemic effects by ingestion: convulsions, respiratory depression, changes in sleep, hallucinations, muscle contractions, somnolence, blood pressure decrease, coma, cyanosis, dyspnea, and ataxia. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. Used in the treatment of depression. When heated to decomposition it emits very toxic fumes of HCl and NOx. See also ELAVIL.

Veterinary Drugs and Treatments

Amitriptyline has been used for behavioral conditions such as separation anxiety or generalized anxiety in dogs, and excessive grooming, spraying and anxiety in cats. Amitriptyline may be useful for adjunctive treatment of pruritus, or chronic pain of neuropathic origin in dogs and cats. In cats, it potentially could be useful for adjunctive treatment of lower urinary tract disease. Amitriptyline has been tried to reduce feather plucking in birds.

Drug interactions

Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids.
Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone - avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with dronedarone.
Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and delamanid - avoid with moxifloxacin.
Anticoagulants: may alter anticoagulant effect of coumarins.
Antidepressants: possibly increased serotonergic effects with duloxetine; enhanced CNS excitation and hypertension with MAOIs and moclobemide; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram - avoid; possible increased risk of convulsions with vortioxetine; concentration reduced by St John’s wort.
Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, phenobarbital and possibly fosphenytoin, phenytoin and primidone.
Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, fluphenazine, haloperidol, pimozide, sulpiride and zuclopenthixol - avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics.
Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir.
Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions.
Beta-blockers: increased risk of ventricular arrhythmias with sotalol.
Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal.
Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide.
Dapoxetine: possibly increased risk of serotonergic effects - avoid. Dopaminergics: avoid with entacapone; CNS toxicity reported with selegiline and rasagiline.
Pentamidine: increased risk of ventricular arrhythmias.
Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.

Metabolism

Amitriptyline undergoes extensive first-pass metabolism and is demethylated in the liver by the cytochrome P450 isoenzymes CYP3A4, CYP2C9, and CYP2D6 to its primary active metabolite, nortriptyline. Other paths of metabolism of amitriptyline include hydroxylation (possibly to active metabolites) by CYP2D6 and N-oxidation; nortriptyline follows similar paths. Amitriptyline is excreted in the urine, mainly in the form of its metabolites, either free or in conjugated form.

Amitriptyline hydrochloride Preparation Products And Raw materials

Raw materials

Amitriptyline hydrochloride Supplier

TargetMol Chemicals Inc. Gold
Tel
021-33632979 15002134094
Email
marketing@targetmol.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Email
Sales-CN@TCIchemicals.com
Energy Chemical
Tel
021-58432009 400-005-6266
Email
sales8178@energy-chemical.com